The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial

Cancer Discov. 2011 Oct;1(5):377-80. doi: 10.1158/2159-8290.CD-11-0229.


Herrero and colleagues show that in a phase III randomized trial in Guanacaste, Costa Rica, the use of a human papillomavirus type 16 (HPV16) and HPV18 ASO4-adjuvanted vaccine (Cervarix) resulted in complete efficacy against 12-month persistent HPV16 and HPV18 infections and partial protection against HPV31, 33, and 45 in HPV-naïve young women ages 18 to 25.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Female
  • Human papillomavirus 16 / immunology*
  • Human papillomavirus 18 / immunology*
  • Humans
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Infections / virology*
  • Papillomavirus Vaccines / therapeutic use*


  • Papillomavirus Vaccines